Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.775889
Title: Genetically engineered Mouse Models reveal a tumourigenic collaboration between Sdhb deficiency and oncogenic Hras
Author: Däbritz, Jan Henry Matthias
ISNI:       0000 0004 7963 032X
Awarding Body: University of Glasgow
Current Institution: University of Glasgow
Date of Award: 2019
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Thesis embargoed until 24 Apr 2022
Access from Institution:
Abstract:
The mitochondrial tumour suppressor succinate dehydrogenase is found inactivated in several tumour entities, amongst them SDH-deficient renal cell carcinoma (RCC) and pheochromocytoma/paraganglioma (Pheo/PGL). An in-depth understanding of cooperating events that enable malignant transformation of SDH-deficient tissues and preclinical model systems of SDH-deficient malignancies are still lacking. The first major goal of this thesis project was to generate a genetically engineered model of SDH-deficient RCC as an easy-to-monitor pathology in mice. In addition, we set out to study tissue-specific phenotypes resulting from stochastic Sdhb loss in peripheral organs. Driven by a Cadherin 16 promoter (KspCre) and thus in the distal renal tubular system, a fatal cystic degeneration of Sdhbfl/fl kidneys resulted from Cre expression. Ongoing untargeted metabolomics analyses of kidney, plasma and urine specimens obtained from this model hold potential for discovery of new biomarkers of SDH-deficient tumours. In a RosaCreERT2-based model, dramatic weight loss within the first weeks after transgene induction correlated with succinate accumulation in peripheral organs of Sdhbfl/fl, Hraswt/wt animals. Less intense transgene induction schemes resulted in long-term survival irrespective of Sdhb status. To the best of my knowledge, this work describes the first, albeit not perfect, genetically engineered mouse model of SDH-deficient RCC. Ongoing experimental efforts focus on reliable identification of systemic metabolic biomarkers that could improve monitoring of patients who are at (relapse) risk of SDH-deficient tumours.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.775889  DOI: Not available
Keywords: RC Internal medicine ; RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Share: